Structured programs can make strength training more accessible and sustainable
Whether its due to side effects, insurance changes, or the need for better results, a safe transition ensures continued treatment and minimizes potential side effects
Patients with a history of thyroid cancer should discuss semaglutide use with their oncologist, as GLP-1 agonists are relatively new in this population
Additionally, the crossover design improves statistical efficiency, as the variance between participants is reduced, allowing for a smaller sample size while maintaining the ability to detect significant effects
Key Efficacy Comparison Year 1 Outcomes: For chronic weight management in adults without diabetes, tirzepatide 15 mg achieved a mean 22.5% total body weight reduction in SURMOUNT-1 (N Engl J Med, 2022), while semaglutide 2.4 mg delivered approximately 15% in the STEP program